FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979746593> ?p ?o ?g. }

• W2979746593 endingPage "5533" @default.
• W2979746593 startingPage "5523" @default.
• W2979746593 abstract "// Caitlin D. Lowery 1 , Wayne Blosser 1 , Michele Dowless 1 , Matthew Renschler 1 , Lisa V. Perez 1 , Jennifer Stephens 1 , Bronislaw Pytowski 1 , Heather Wasserstrom 1 , Louis F. Stancato 1 and Beverly Falcon 1 1 Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, USA Correspondence to: Beverly Falcon, email: falcon_beverly_l@lilly.com Keywords: angiogenesis; pediatric cancer; VEGFR2; ramucirumab; DC101 Received: May 24, 2019     Accepted: July 21, 2019     Published: September 17, 2019 ABSTRACT Vascular endothelial growth factor receptor 2 (VEGFR2) is an attractive therapeutic target in solid malignancies due to its central role in tumor angiogenesis. Ramucirumab (Cyramza &#x00AE; , LY3009806) is a human monoclonal antibody specific for VEGFR2 approved for several adult indications and currently in a phase 1 clinical trial for pediatric patients with solid tumors (NCT02564198). Here, we evaluated ramucirumab in vitro and the anti-murine VEGFR2 antibody DC101 in vivo with or without chemotherapy across a range of pediatric cancer models. Ramucirumab abrogated in vitro endothelial cord formation driven by cancer cell lines representing multiple pediatric histologies; this response was independent of the origin of the tumor cell-line. Several pediatric cancer mouse models responded to single agent DC101-mediated VEGFR2 inhibition with tumor growth delay. Preclinical stable disease and partial xenograft regressions were observed in mouse models of Ewing&#x2019;s sarcoma, synovial sarcoma, neuroblastoma, and desmoplastic small round cell tumor treated with DC101 and cytotoxic chemotherapy. In contrast, DC101 treatment in osteosarcoma models had limited efficacy alone or in combination with chemotherapeutics. Our data indicate differential efficacy of targeting the VEGFR2 pathway in pediatric models and support the continued evaluation of VEGFR2 inhibition in combination with cytotoxic chemotherapy in multiple pediatric indications." @default.
• W2979746593 created "2019-10-18" @default.
• W2979746593 creator A5011257876 @default.
• W2979746593 creator A5013385271 @default.
• W2979746593 creator A5019317536 @default.
• W2979746593 creator A5023666606 @default.
• W2979746593 creator A5032518555 @default.
• W2979746593 creator A5044699736 @default.
• W2979746593 creator A5049945207 @default.
• W2979746593 creator A5055858360 @default.
• W2979746593 creator A5063464560 @default.
• W2979746593 creator A5071842124 @default.
• W2979746593 date "2019-09-17" @default.
• W2979746593 modified "2023-10-14" @default.
• W2979746593 title "Anti-VEGFR2 therapy delays growth of preclinical pediatric tumor models and enhances anti-tumor activity of chemotherapy" @default.
• W2979746593 cites W1576183422 @default.
• W2979746593 cites W1725090888 @default.
• W2979746593 cites W1756949381 @default.
• W2979746593 cites W1987656859 @default.
• W2979746593 cites W1998720050 @default.
• W2979746593 cites W2007431337 @default.
• W2979746593 cites W2061440729 @default.
• W2979746593 cites W2064283997 @default.
• W2979746593 cites W2073342125 @default.
• W2979746593 cites W2086619383 @default.
• W2979746593 cites W2157354207 @default.
• W2979746593 cites W2166283776 @default.
• W2979746593 cites W2255518001 @default.
• W2979746593 cites W2293809486 @default.
• W2979746593 cites W2342679175 @default.
• W2979746593 cites W2416680584 @default.
• W2979746593 cites W2592185869 @default.
• W2979746593 cites W2601868035 @default.
• W2979746593 cites W2620790632 @default.
• W2979746593 cites W2719499442 @default.
• W2979746593 cites W2748850503 @default.
• W2979746593 cites W2752414510 @default.
• W2979746593 cites W2753841357 @default.
• W2979746593 cites W2761476383 @default.
• W2979746593 cites W2765300910 @default.
• W2979746593 cites W2769836287 @default.
• W2979746593 cites W2789869568 @default.
• W2979746593 cites W2789924919 @default.
• W2979746593 cites W2793943975 @default.
• W2979746593 cites W2800353792 @default.
• W2979746593 cites W2891616394 @default.
• W2979746593 cites W2894327063 @default.
• W2979746593 cites W2921434986 @default.
• W2979746593 cites W4250428608 @default.
• W2979746593 doi "https://doi.org/10.18632/oncotarget.27148" @default.
• W2979746593 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6756863" @default.
• W2979746593 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31565186" @default.
• W2979746593 hasPublicationYear "2019" @default.
• W2979746593 type Work @default.
• W2979746593 sameAs 2979746593 @default.
• W2979746593 citedByCount "10" @default.
• W2979746593 countsByYear W29797465932020 @default.
• W2979746593 countsByYear W29797465932021 @default.
• W2979746593 countsByYear W29797465932022 @default.
• W2979746593 countsByYear W29797465932023 @default.
• W2979746593 crossrefType "journal-article" @default.
• W2979746593 hasAuthorship W2979746593A5011257876 @default.
• W2979746593 hasAuthorship W2979746593A5013385271 @default.
• W2979746593 hasAuthorship W2979746593A5019317536 @default.
• W2979746593 hasAuthorship W2979746593A5023666606 @default.
• W2979746593 hasAuthorship W2979746593A5032518555 @default.
• W2979746593 hasAuthorship W2979746593A5044699736 @default.
• W2979746593 hasAuthorship W2979746593A5049945207 @default.
• W2979746593 hasAuthorship W2979746593A5055858360 @default.
• W2979746593 hasAuthorship W2979746593A5063464560 @default.
• W2979746593 hasAuthorship W2979746593A5071842124 @default.
• W2979746593 hasBestOaLocation W29797465931 @default.
• W2979746593 hasConcept C121608353 @default.
• W2979746593 hasConcept C126322002 @default.
• W2979746593 hasConcept C142724271 @default.
• W2979746593 hasConcept C143998085 @default.
• W2979746593 hasConcept C2776694085 @default.
• W2979746593 hasConcept C2777760704 @default.
• W2979746593 hasConcept C2778256501 @default.
• W2979746593 hasConcept C2779551604 @default.
• W2979746593 hasConcept C2780394083 @default.
• W2979746593 hasConcept C2993561819 @default.
• W2979746593 hasConcept C502942594 @default.
• W2979746593 hasConcept C71924100 @default.
• W2979746593 hasConceptScore W2979746593C121608353 @default.
• W2979746593 hasConceptScore W2979746593C126322002 @default.
• W2979746593 hasConceptScore W2979746593C142724271 @default.
• W2979746593 hasConceptScore W2979746593C143998085 @default.
• W2979746593 hasConceptScore W2979746593C2776694085 @default.
• W2979746593 hasConceptScore W2979746593C2777760704 @default.
• W2979746593 hasConceptScore W2979746593C2778256501 @default.
• W2979746593 hasConceptScore W2979746593C2779551604 @default.
• W2979746593 hasConceptScore W2979746593C2780394083 @default.
• W2979746593 hasConceptScore W2979746593C2993561819 @default.
• W2979746593 hasConceptScore W2979746593C502942594 @default.
• W2979746593 hasConceptScore W2979746593C71924100 @default.
• W2979746593 hasIssue "53" @default.
• W2979746593 hasLocation W29797465931 @default.

• next